United Therapeutics Corporation | Large-cap | Healthcare
$287.35
1.08%
| United Therapeutics Stock Comparison:
United Therapeutics vs ZoetisUnited Therapeutics vs Haleon Plc - ADRUnited Therapeutics vs Intra-CellularUnited Therapeutics vs NeurocrineUnited Therapeutics vs ViatrisUnited Therapeutics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2.9B
Gross Profit 2.6B 89.24%
Operating Income 1.4B 50.33%
Net Income 1.2B 41.53%
EPS (Diluted) $24.64

Balance Sheet Metrics

Total Assets 7.4B
Total Liabilities 920.0M
Shareholders Equity 6.4B
Debt to Equity 0.14

Cash Flow Metrics

Operating Cash Flow 1.3B
Free Cash Flow 1.1B

Revenue & Profitability Trend

United Therapeutics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 2.9B 2.3B 1.9B 1.7B 1.5B
Cost of Goods Sold 309.7M 257.5M 151.6M 122.5M 108.1M
Gross Profit 2.6B 2.1B 1.8B 1.6B 1.4B
Operating Expenses 1.1B 885.1M 805.0M 1.0B 781.6M
Operating Income 1.4B 1.2B 979.7M 555.9M 593.6M
Pre-tax Income 1.5B 1.3B 950.6M 593.9M 638.9M
Income Tax 343.9M 289.5M 223.3M 118.1M 124.1M
Net Income 1.2B 984.8M 727.3M 475.8M 514.8M
EPS (Diluted) $24.64 $19.81 $15.00 $10.06 $11.54

Income Statement Trend

United Therapeutics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 3.9B 3.6B 3.4B 2.3B 2.2B
Non-Current Assets 3.5B 3.6B 2.7B 2.8B 2.4B
Total Assets 7.4B 7.2B 6.0B 5.2B 4.6B
Liabilities
Current Liabilities 738.1M 804.4M 343.2M 305.4M 323.3M
Non-Current Liabilities 181.9M 377.8M 904.6M 904.8M 896.5M
Total Liabilities 920.0M 1.2B 1.2B 1.2B 1.2B
Equity
Total Shareholders Equity 6.4B 6.0B 4.8B 4.0B 3.4B

Balance Sheet Composition

United Therapeutics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 1.2B 984.8M 727.3M 475.8M 514.8M
Operating Cash Flow 1.3B 917.3M 752.2M 568.4M 706.0M
Investing Activities
Capital Expenditures -246.5M -230.4M -138.8M -120.8M -56.9M
Investing Cash Flow 417.2M -719.6M -811.5M -486.9M -738.5M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -1.8B -216.5M -18.9M -10.8M -105.4M
Free Cash Flow 1.1B 747.6M 663.7M 477.4M 696.4M

Cash Flow Trend

United Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 11.41
Forward P/E 10.27
Price to Book 1.90
Price to Sales 4.31
PEG Ratio 10.27

Profitability Ratios

Profit Margin 40.44%
Operating Margin 48.31%
Return on Equity 19.94%
Return on Assets 12.97%

Financial Health

Current Ratio 5.46
Debt to Equity 2.94
Beta 0.58

Per Share Data

EPS (TTM) $25.09
Book Value per Share $151.02
Revenue per Share $67.02

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
uthr 12.9B 11.41 1.90 19.94% 40.44% 2.94
Zoetis 70.3B 28.34 15.12 52.09% 27.12% 145.63
Haleon Plc - ADR 47.2B 25.01 5.88 8.95% 12.84% 63.41
Intra-Cellular 14.0B -183.15 12.20 -8.58% -10.97% 1.48
Neurocrine 12.5B 42.90 4.94 12.43% 12.68% 19.45
Viatris 10.4B 235.80 0.67 -21.25% -26.45% 92.38

Financial data is updated regularly. All figures are in the company's reporting currency.